(Q37987837)

English

Evacetrapib

scientific article published on June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Evacetrapib (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Stephen J Nicholls

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Current cardiology reports

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

245-250

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

https://scigraph.springernature.com/pub.10.1007/s11886-012-0252-3

0 references

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

The forgotten majority: unfinished business in cardiovascular risk reduction

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

High-density lipoprotein--the clinical implications of recent studies

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effects of the amount and intensity of exercise on plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Extended-release niacin or ezetimibe and carotid intima-media thickness.

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effects of torcetrapib in patients at high risk for coronary events

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Safety and tolerability of dalcetrapib

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Safety of anacetrapib in patients with or at high risk for coronary heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0252-3

21 January 2018

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The failure of torcetrapib: was it the molecule or the mechanism?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CETP and atherosclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits

1 reference

https://pubmed.ncbi.nlm.nih.gov/22362199

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11886-012-0252-3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37987837&oldid=2108924364"